Tags

Type your tag names separated by a space and hit enter

Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast.
J Asthma. 2007 Apr; 44(3):213-7.JA

Abstract

The objective of this double-blind cross-over study was to evaluate montelukast for the prevention of exercise-induced bronchoconstriction (EIB). Sixty-two patients with EIB (post-exercise decrease in forced expiratory volume in 1 second (FEV(1)) > or = 20% at pre-randomization) were randomized to montelukast 10 mg or placebo, followed by exercise-challenge 2, 12, and 24 hours postdose. The primary endpoint was the maximum percent-fall in FEV(1) (from pre-exercise FEV(1)) during 60 minutes after exercise-challenge at 2 hours postdose. This endpoint was improved after montelukast (mean +/- SD = 11.7% +/- 10.8) versus placebo (17.5% +/- 13.8) (p < or = 0.001); numerically greater improvements were seen at 12 hours and 24 hours. A quicker time to recovery after challenge (p < or = 0.001) and a smaller area under the curve for percent-fall in FEV(1) during 60 minutes after challenge (p < or = 0.01) were seen with montelukast at 2 hours. At this timepoint, more patients taking montelukast (45/54) than taking placebo (37/54) were protected against EIB (p = 0.039). We concluded that montelukast provided significant protection against EIB at 2 hours after a single dose.

Authors+Show Affiliations

Merck Research Laboratories. Rahway, NJ 07065, USA. george.philip@merck.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17454341

Citation

Philip, George, et al. "Protection Against Exercise-induced Bronchoconstriction Two Hours After a Single Oral Dose of Montelukast." The Journal of Asthma : Official Journal of the Association for the Care of Asthma, vol. 44, no. 3, 2007, pp. 213-7.
Philip G, Villarán C, Pearlman DS, et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma. 2007;44(3):213-7.
Philip, G., Villarán, C., Pearlman, D. S., Loeys, T., Dass, S. B., & Reiss, T. F. (2007). Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. The Journal of Asthma : Official Journal of the Association for the Care of Asthma, 44(3), 213-7.
Philip G, et al. Protection Against Exercise-induced Bronchoconstriction Two Hours After a Single Oral Dose of Montelukast. J Asthma. 2007;44(3):213-7. PubMed PMID: 17454341.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. AU - Philip,George, AU - Villarán,Cesar, AU - Pearlman,David S, AU - Loeys,Tom, AU - Dass,S Balachandra, AU - Reiss,Theodore F, PY - 2007/4/25/pubmed PY - 2007/5/16/medline PY - 2007/4/25/entrez SP - 213 EP - 7 JF - The Journal of asthma : official journal of the Association for the Care of Asthma JO - J Asthma VL - 44 IS - 3 N2 - The objective of this double-blind cross-over study was to evaluate montelukast for the prevention of exercise-induced bronchoconstriction (EIB). Sixty-two patients with EIB (post-exercise decrease in forced expiratory volume in 1 second (FEV(1)) > or = 20% at pre-randomization) were randomized to montelukast 10 mg or placebo, followed by exercise-challenge 2, 12, and 24 hours postdose. The primary endpoint was the maximum percent-fall in FEV(1) (from pre-exercise FEV(1)) during 60 minutes after exercise-challenge at 2 hours postdose. This endpoint was improved after montelukast (mean +/- SD = 11.7% +/- 10.8) versus placebo (17.5% +/- 13.8) (p < or = 0.001); numerically greater improvements were seen at 12 hours and 24 hours. A quicker time to recovery after challenge (p < or = 0.001) and a smaller area under the curve for percent-fall in FEV(1) during 60 minutes after challenge (p < or = 0.01) were seen with montelukast at 2 hours. At this timepoint, more patients taking montelukast (45/54) than taking placebo (37/54) were protected against EIB (p = 0.039). We concluded that montelukast provided significant protection against EIB at 2 hours after a single dose. SN - 0277-0903 UR - https://www.unboundmedicine.com/medline/citation/17454341/Protection_against_exercise_induced_bronchoconstriction_two_hours_after_a_single_oral_dose_of_montelukast_ L2 - https://www.tandfonline.com/doi/full/10.1080/02770900701209806 DB - PRIME DP - Unbound Medicine ER -